Drug intelligence / Profile preview

DCN-01

Development stage: Phase 2
Lead developer: Icon
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

DCN-01 is a small molecule drug developed by Deacon Biosciences for the treatment of eye infections. Its precise mechanism of action is currently unknown. The drug has undergone Phase 2 clinical trials, specifically evaluating its anti-microbial efficacy and safety when administered topically to the periocular region in healthy volunteers as part of a proof-of-concept study[1][2][3]. There are no FDA designations or approved indications for DCN-01 at this time.

Beyond the preview

Go deeper on DCN-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCN-01.

Explore the full profile